InsiderClue
Stocks · Health care · Biological Products, (No Diagnostic Substances)

Krystal Biotech, Inc.

KRYS Clue Score76
United States Fiscal year ends December CIK 0001711279
$331.61 +1.32% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $331.61 +554.19% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 20 Sep 2017. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back. P/E and P/FCF are the market value over the last full fiscal year's net income or free cash flow, as public on each day, so they step once a year when the annual report comes out. A hatched band marks a stretch with none: a year of net loss, or of cash burnt.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2016Operating income−1.1Net income−1.2Fiscal year 2017Operating income−4.8Net income−7.9Fiscal year 2018Operating income−11.9Net income−10.9Fiscal year 2019Operating income−22.1Net income−19.1Fiscal year 2020Operating income−33.0Net income−32.2EPS, diluted−1.71Fiscal year 2021Revenue0.0Operating income−68.3Net income−69.6EPS, diluted−3.13Fiscal year 2022Revenue0.0Operating income−145.2Net income−140.0EPS, diluted−5.49Fiscal year 2023Revenue50.7Operating income−109.6Net income10.9EPS, diluted0.39Fiscal year 2024Revenue290.5 +473.0%Operating income65.7Net income89.2 +715.6%EPS, diluted3.00 +669.2%Fiscal year 2025Revenue389.1 +33.9%Operating income161.3Net income204.8 +129.7%EPS, diluted6.84 +128.0%
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue n/a n/a n/a n/a n/a 0.0 0.0 50.7 290.5 389.1
Growth +473.0% +33.9%
Operating income −1.1 −4.8 −11.9 −22.1 −33.0 −68.3 −145.2 −109.6 65.7 161.3
Net income −1.2 −7.9 −10.9 −19.1 −32.2 −69.6 −140.0 10.9 89.2 204.8
Growth +715.6% +129.7%
EPS, diluted n/a n/a n/a n/a −1.71 −3.13 −5.49 0.39 3.00 6.84
Growth +669.2% +128.0%

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2016Fiscal year 2017Fiscal year 2018Fiscal year 2019Fiscal year 2020Fiscal year 2021Fiscal year 2022Fiscal year 2023Operating margin−216.2%Net margin21.6%Free cash flow margin−198.4%Fiscal year 2024Operating margin22.6%Net margin30.7%Free cash flow margin41.0%Fiscal year 2025Operating margin41.5%Net margin52.6%Free cash flow margin48.5%
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating margin n/a n/a n/a n/a n/a n/a n/a −216.2% 22.6% 41.5%
Net margin n/a n/a n/a n/a n/a n/a n/a 21.6% 30.7% 52.6%
Free cash flow margin n/a n/a n/a n/a n/a n/a n/a −198.4% 41.0% 48.5%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2016Operating cash flow−1.3Capital expenditure−0.0Free cash flow−1.3Fiscal year 2017Operating cash flow−3.9Capital expenditure−0.2Free cash flow−4.1Fiscal year 2018Operating cash flow−9.4Capital expenditure−2.2Free cash flow−11.7Fiscal year 2019Operating cash flow−18.7Capital expenditure−6.4Free cash flow−25.1Fiscal year 2020Operating cash flow−26.1Capital expenditure−14.8Free cash flow−40.9Fiscal year 2021Operating cash flow−47.9Capital expenditure−68.3Free cash flow−116.3Fiscal year 2022Operating cash flow−100.6Capital expenditure−53.0Free cash flow−153.5Fiscal year 2023Operating cash flow−88.8Capital expenditure−11.8Free cash flow−100.6Fiscal year 2024Operating cash flow123.4Capital expenditure−4.2Free cash flow119.2Fiscal year 2025Operating cash flow200.9Capital expenditure−12.0Free cash flow188.9 +58.5%
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow −1.3 −3.9 −9.4 −18.7 −26.1 −47.9 −100.6 −88.8 123.4 200.9
Capital expenditure −0.0 −0.2 −2.2 −6.4 −14.8 −68.3 −53.0 −11.8 −4.2 −12.0
Free cash flow −1.3 −4.1 −11.7 −25.1 −40.9 −116.3 −153.5 −100.6 119.2 188.9
Growth +58.5%

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2016Cash1.9Shareholders’ equity0.3Fiscal year 2017Cash49.6Shareholders’ equity49.5Fiscal year 2018Cash103.7Shareholders’ equity113.2Fiscal year 2019Cash187.5Shareholders’ equity202.9Fiscal year 2020Cash268.3Shareholders’ equity292.1Fiscal year 2021Cash341.2Shareholders’ equity593.6Fiscal year 2022Cash161.9Shareholders’ equity522.2Fiscal year 2023Cash358.3Shareholders’ equity778.6Fiscal year 2024Cash344.9Shareholders’ equity946.4Fiscal year 2025Cash496.3Shareholders’ equity1,219.6
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Cash 1.9 49.6 103.7 187.5 268.3 341.2 161.9 358.3 344.9 496.3
Shareholders’ equity 0.3 49.5 113.2 202.9 292.1 593.6 522.2 778.6 946.4 1,219.6

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2016 31 Dec 2016 FY2017 31 Dec 2017 FY2018 31 Dec 2018 FY2019 31 Dec 2019 FY2020 31 Dec 2020 FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Revenue and profit
n/a n/a n/a n/a n/a 0.0 0.0 50.7 290.5 389.1
Growth +473.0% +33.9%
0.7 3.2 7.8 15.6 17.9 27.9 42.5 46.4 53.6 58.0
0.4 1.6 4.2 6.5 15.1 40.4 77.7 98.3 113.6 146.7
−1.1 −4.8 −11.9 −22.1 −33.0 −68.3 −145.2 −109.6 65.7 161.3
Growth +145.3%
n/a n/a n/a n/a n/a −69.6 −140.0 12.9 95.4 189.5
n/a 0.0 0.0 0.0 0.0 0.0 0.0 2.0 6.2 −15.4
−1.2 −7.9 −10.9 −19.1 −32.2 −69.6 −140.0 10.9 89.2 204.8
Growth +715.6% +129.7%
Per share
n/a n/a n/a n/a −1.71 −3.13 −5.49 0.40 3.12 7.08
n/a n/a n/a n/a −1.71 −3.13 −5.49 0.39 3.00 6.84
Growth +669.2% +128.0%
n/a n/a n/a n/a 18.8 22.2 25.5 27.2 28.6 28.9
n/a n/a n/a n/a 18.8 22.2 25.5 27.8 29.7 30.0
Growth +18.1% +14.8% +8.9% +7.2% +0.7%

Five years in brief

Worked out from the figures above, not from a press release
  • The diluted share count rose 59.4% in five years, which is dilution.
  • A net loss in 7 of 10 years on file.